JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Avita Therapeutics Inc

Cerrado

4.3 1.9

Resumen

Variación precio

24h

Actual

Mínimo

4.21

Máximo

4.36

Métricas clave

By Trading Economics

Ingresos

1.6M

-12M

Ventas

554K

18M

Margen de beneficios

-65.968

Empleados

226

EBITDA

1.6M

-9.7M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+46.19% upside

Dividendos

By Dow Jones

Próximas Ganancias

14 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

17M

140M

Apertura anterior

2.4

Cierre anterior

4.3

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Avita Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 23:53 UTC

Ganancias

Naver Posts Weaker First-Quarter Earnings

29 abr 2026, 23:41 UTC

Acciones populares

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 abr 2026, 23:55 UTC

Ganancias

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 abr 2026, 23:54 UTC

Ganancias

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 abr 2026, 23:52 UTC

Ganancias

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 abr 2026, 23:51 UTC

Ganancias

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 abr 2026, 23:51 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 abr 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 abr 2026, 23:24 UTC

Ganancias

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 abr 2026, 23:22 UTC

Ganancias

China Longyuan 1Q Net CNY1.70B, Down 14%

29 abr 2026, 23:22 UTC

Ganancias

China Longyuan: Power Generation Down 2.9% as of End-March

29 abr 2026, 23:20 UTC

Ganancias

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 abr 2026, 23:20 UTC

Ganancias

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 abr 2026, 23:19 UTC

Ganancias

China Vanke 1Q Loss Narrows>000002.SZ

29 abr 2026, 23:18 UTC

Ganancias

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 abr 2026, 23:17 UTC

Ganancias

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 abr 2026, 23:15 UTC

Ganancias

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 abr 2026, 23:15 UTC

Ganancias

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 abr 2026, 23:13 UTC

Ganancias

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 abr 2026, 23:12 UTC

Ganancias

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 abr 2026, 23:11 UTC

Ganancias

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 abr 2026, 23:11 UTC

Ganancias

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 abr 2026, 23:04 UTC

Ganancias

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 abr 2026, 23:04 UTC

Ganancias

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparación entre iguales

Cambio de precio

Avita Therapeutics Inc previsión

Precio Objetivo

By TipRanks

46.19% repunte

Estimación a 12 Meses

Media 6.33 USD  46.19%

Máximo 10 USD

Mínimo 3.5 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avita Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.83 / 9.77Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat